Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
ACG Q4 2025 Earnings Call - Revenues stable but one-time RMB33.9m goodwill hit turns an operational improvement into a quarterly loss
ACG reported Q4 2025 net revenue of RMB 89.1 million, down 11.7% year over year, while full-year revenue held flat at RMB 268.1 million. The headline swing to a Q4 net loss of RMB 26.3 million was dri...
- Q4 2025 net revenue RMB 89.1 million, down 11.7% year over year; full-year 2025 revenue RMB 268.1 million, essentially flat versus 2024.
- Q4 gross profit fell to RMB 30.2 million from RMB 63.7 million a year earlier, gross margin compressed to 56.4% from 63.1% due to higher outsourcing and part-time teacher costs.
- Company recorded a one-time goodwill impairment of RMB 33.9 million in Q4 2025, equivalent to about $4.8 million, which flipped operating income to a loss.
- +12 more takeaways
Journey Medical Full Year 2025 Earnings Call - EMROSI launch drives strong prescriptions and adjusted EBITDA positivity
Journey Medical used 2025 to reinvent itself around EMROSI, its new oral rosacea therapy. Launched commercially in April, EMROSI generated $14.7 million in net sales across three quarters, about 53,00...
- EMROSI commercial launch began in late March 2025, with promotion starting in April, and produced $14.7 million in net sales across the three quarters it was available last year.
- Total EMROSI prescriptions reached approximately 53,000 since launch, with about 3,500 unique prescribers having written at least one script to date.
- EMROSI prescription momentum accelerated in Q4, with Q4 prescriptions annualized to a run rate of roughly 126,000 scripts; management expects further sequential growth into 2026.
- +12 more takeaways
Stardust Power Inc. Year-end 2025 Earnings Call - Muskogee Refinery De-risked, Moving to Project Financing
Stardust used 2025 to methodically de-risk its planned Muskogee lithium refinery, checking engineering, permitting, supply and commercial boxes that lenders and strategic partners demand. Management s...
- Company completed FEL-3 engineering study for the Muskogee lithium refinery with Primero USA, a milestone management says is required to advance project planning and financing.
- Independent review by Black & Veatch concluded the project has low technical and design risk and that phase one production targets are achievable, providing third-party validation.
- Stardust secured an air quality construction permit from the Oklahoma Department of Environmental Quality, with the facility qualifying as a minor source under state and federal air rules, materially reducing regulatory timeline risk.
- +13 more takeaways
Dyadic International Inc. Full Year 2025 Earnings Call - Transitioning to Commercial Revenues with Early Product Launches and Runway into 2027
Dyadic spent 2025 moving from platform R&D to commercial execution, signing distribution and manufacturing partnerships, launching products, and booking grant funding. Revenues edged lower to $3.09 mi...
- Company repositioned as Dyadic Applied BioSolutions and signaled a strategic shift from development-stage platform work to commercial product sales and partner-driven revenues.
- Total 2025 revenue was $3.09 million, down from $3.5 million in 2024, driven by lower R&D collaboration and reduced license and milestone income, partially offset by increased grant revenue.
- Net loss for 2025 widened to $7.36 million, or $0.23 per share, compared to a $5.81 million loss in 2024, reflecting continued investment during the commercial transition.
- +11 more takeaways
Planet 13 Holdings Q4 2025 Earnings Call - Stabilization in Q4, 2026 pivot to positive cash flow after California exit and Nevada cuts
Planet 13 reported a stabilizing quarter as restructuring and portfolio cleanup began to show through the numbers. Revenue rose sequentially 8% to $25.2 million, retail drove the improvement and gross...
- Sequential revenue improvement, total Q4 revenue $25.2 million, up roughly 8% from Q3 ($23.3 million).
- Retail stabilization: SuperStore and neighborhood network combined $23.2 million vs $21.3 million in Q3; SuperStore (including DAZED) $9.2 million, essentially flat with Q3 despite F1 disruption.
- Florida momentum: Neighborhood stores generated $14 million with Florida at $10.3 million, though that figure included a one-time loyalty accrual adjustment; excluding California, non-SuperStore neighborhood stores grew about 8% sequentially.
- +12 more takeaways
Health In Tech Q4 2025 Earnings Call - AI underwriting scales, revenue +71% and 2026 guide $45M-$50M
Health In Tech closed its first public year with a clear growth story and a product pitch: revenue surged 71% to $33.3 million in 2025, driven by distribution expansion, platform upgrades and program ...
- 2025 was Health In Tech’s first year as a public company, with full-year revenue up 71% to $33.3 million and Q4 revenue up 53% to $7.5 million.
- Company provided 2026 revenue guidance of $45 million to $50 million, implying roughly 35% to 50% year-over-year growth versus 2025.
- Management attributes growth to three drivers: distribution expansion, platform advancement (eDIYBS), and program innovation (Three-Year Rate Stabilization).
- +13 more takeaways
Navan Q4 FY2026 Earnings Call - AI-fueled GBV acceleration and first-time free cash flow positivity
Navan closed FY2026 with clear operational momentum. Q4 revenue was $178 million, up 35% year over year, while gross booking value hit $2.3 billion, up 42%. Management pointed to strong PLG and SLG dy...
- Q4 revenue $178 million, up 35% year over year; GBV $2.3 billion, up 42% year over year.
- Management reported record customer experience metrics: NPS 47 and CSAT 96 in Q4, which they present as proof of product-market fit.
- Navan turned free cash flow positive for the first time, one year ahead of its plan.
- +11 more takeaways
MillerKnoll Q3 FY2026 Earnings Call - Contract strength and debt reduction offset weather; Middle East conflict to cost ~$0.09-$0.10 EPS in Q4
MillerKnoll delivered a solid Q3 FY2026 with sales of $927 million, orders of $932 million, and operating leverage in North America Contract that drove gross margin expansion. The company generated $6...
- Consolidated net sales $927 million, up 5.8% year over year, organic sales up 3.8%.
- Quarterly orders $932 million, up 9.2% reported and 7.2% organically; backlog $712 million, up 3.7% year over year.
- Adjusted EPS of $0.43 in Q3, versus $0.44 a year ago.
- +12 more takeaways
SeaStar Medical Q4 2025 Earnings Call - Pivotal adult AKI trial passes midpoint as company pushes for modular PMA
SeaStar Medical closed 2025 with early commercial traction in pediatrics and a high-stakes pivot toward a much larger adult acute kidney injury market. QUELIMMUNE generated $1.1 million in 2025 revenu...
- NEUTRALIZE-AKI pivotal trial is 181 of 339 enrolled, just over 50% complete, with target enrollment completion around year-end 2026 and potential top-line results mid-2027.
- Primary endpoint of NEUTRALIZE-AKI is a composite of 90-day mortality or dialysis dependence; trial tests up to ten sequential 24-hour SCD treatments in CRRT patients.
- Company pursuing a modular PMA submission strategy for the adult AKI indication and has FDA Breakthrough Device Designation to potentially accelerate review.
- +12 more takeaways
WidePoint Corporation Q4 2025 Earnings Call - CWMS 3.0 Delays Persist, SaaS/DaaS Carrier Win Poised to Drive Margin Lift
WidePoint spent most of the call steadying nerves around a delayed DHS recompete while pointing to tangible commercial progress that can actually move the needle. Management framed CWMS 3.0 timing as ...
- CWMS 3.0 award remains delayed due to government and DHS funding and leadership disruptions; management insists delays are timing issues, not a change in competitive standing.
- WidePoint received a 6-month extension under CWMS 2.0 (2-month base plus four 1-month options), providing DHS flexibility through May 2026 and roughly $80 million of remaining contract ceiling under CWMS 2.0.
- Management expects some form of DHS update by mid-Q2 2026, either an award or another extension, and says the company is positioned to win the CWMS 3.0 recompete if/when it is announced.
- +12 more takeaways